TY - JOUR
T1 - Breast cancer, version 4.2021 featured updates to the NCCN guidelines
AU - Gradishar, William J.
AU - Moran, Meena S.
AU - Abraham, Jame
AU - Aft, Rebecca
AU - Agnese, Doreen
AU - Allison, Kimberly H.
AU - Blair, Sarah L.
AU - Burstein, Harold J.
AU - Dang, Chau
AU - Elias, Anthony D.
AU - Giordano, Sharon H.
AU - Goetz, Matthew P.
AU - Goldstein, Lori J.
AU - Hurvitz, Sara A.
AU - Isakoff, Steven J.
AU - Jankowitz, Rachel C.
AU - Javid, Sara H.
AU - Krishnamurthy, Jairam
AU - Leitch, Marilyn
AU - Lyons, Janice
AU - Matro, Jennifer
AU - Mayer, Ingrid A.
AU - Mortimer, Joanne
AU - O'Regan, Ruth M.
AU - Patel, Sameer A.
AU - Pierce, Lori J.
AU - Rugo, Hope S.
AU - Sitapati, Amy
AU - Smith, Karen Lisa
AU - Smith, Mary Lou
AU - Soliman, Hatem
AU - Stringer-Reasor, Erica M.
AU - Telli, Melinda L.
AU - Ward, John H.
AU - Wisinski, Kari B.
AU - Young, Jessica S.
AU - Burns, Jennifer L.
AU - Kumar, Rashmi
N1 - Funding Information:
Ingrid A. Mayer, MD, Panel Member, has disclosed receiving consulting fees from AbbVie, Inc., AstraZeneca Pharmaceuticals LP, Genentech, Inc., GlaxoSmithKline, Immunomedics, Inc., Novartis Pharmaceuticals Corporation, Eli Lilly and Company, MacroGenics, Inc., Puma Biotechnology, and Seattle Genetics, Inc.; honoraria from AstraZeneca Pharmaceuticals LP, Genentech, Inc., and Novartis Pharmaceuticals Corporation; and grant/research support from Genentech, Inc., Novartis Pharmaceuticals Corporation, and Pfizer Inc.
Funding Information:
This activity is supported by educational grants from Agios Pharmaceuticals; AstraZeneca; Clovis Oncology, Inc.; Daiichi Sankyo; Eisai; Epizyme Inc.; Novartis; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. This activity is supported by an independent medical education grant from Bristol-Myers Squibb, and Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is supported by an independent medical educational grant from Mylan Inc. This activity is supported by a medical education grant from Karyopharm Therapeutics. This activity is supported by an independent educational grant from AbbVie.
Publisher Copyright:
© 2021 Harborside Press. All rights reserved.
PY - 2021/5
Y1 - 2021/5
N2 - The NCCN Guidelines for Breast Cancer include up-to-date guidelines for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, male breast cancer, and breast cancer during pregnancy. These guidelines are developed by a multidisciplinary panel of representatives from NCCN Member Institutions with breast cancer-focused expertise in the fields of medical oncology, surgical oncology, radiation oncology, pathology, reconstructive surgery, and patient advocacy. These NCCN Guidelines Insights focus on the most recent updates to recommendations for adjuvant systemic therapy in patients with nonmetastatic, early-stage, hormone receptor-positive, HER2-negative breast cancer.
AB - The NCCN Guidelines for Breast Cancer include up-to-date guidelines for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, male breast cancer, and breast cancer during pregnancy. These guidelines are developed by a multidisciplinary panel of representatives from NCCN Member Institutions with breast cancer-focused expertise in the fields of medical oncology, surgical oncology, radiation oncology, pathology, reconstructive surgery, and patient advocacy. These NCCN Guidelines Insights focus on the most recent updates to recommendations for adjuvant systemic therapy in patients with nonmetastatic, early-stage, hormone receptor-positive, HER2-negative breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=85106923703&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2021.0023
DO - 10.6004/jnccn.2021.0023
M3 - Article
C2 - 34030128
AN - SCOPUS:85106923703
SN - 1540-1405
VL - 19
SP - 484
EP - 494
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 5
ER -